Amanda Easey

Senior associate

Dr Amanda Easey is a senior associate in the intellectual property team in London. She specialises in advising clients operating in technically complex fields. Her work encompasses patent litigation, regulatory advice and freedom to operate opinions.

She also has experience in advising on a variety of related legal issues, including patent licensing and royalty disputes and drafting commercial agreements. Amanda has represented clients in the Patents Court (a specialised division of the Business and Property Courts in England and Wales) and at appellate level. She has particular expertise in advising on launch strategies for orphan medicines. Her work in this sector has encompassed questions relating to exclusivity and complex product labelling strategies relating to potentially overlapping disease classifications and therapeutic indications.

I enjoy working with regulatory specialists to identify and resolve complicated questions about the scope of orphan drug exclusivities. This allows me to work on challenging questions at the intersection between medicine and law, enabling me to deploy my medical knowledge and experience to give practical answers to my clients.

Amanda Easey, Senior associate

Amanda worked as a medical doctor before retraining as a solicitor at a multinational law firm in 2005. She worked at a specialist IP law firm for over 12 years before joining Penningtons Manches Cooper in 2022. Her medical background and experience have proved advantageous to many of her clients in the life sciences sector, particularly those interested in launching pharmaceuticals and biosimilar medicines onto the UK and European markets. She has advised on patent issues in a diverse range of therapy areas, including ophthalmology, oncology, audiology, haematology, rheumatology and women’s health.

Recent work highlights

Pharmaceutical patent litigation

Representing a multinational generic pharmaceutical company in successful legal proceedings in the Patents Court and the Court of Appeal relating to early market access for a patented haematology product.

Orphan drugs

Advising on obtaining a restricted label for a pharmaceutical product designated as an orphan drug.

Freedom to operate advice

Advising numerous generic pharmaceutical companies on their launch strategies for the UK market, including patent design-around options and ‘clearing the way’.

Advising on orphan drug market protection

Analysing the scope of exclusivity afforded by an existing EU orphan drug designation with the objective of helping the client to devise a regulatory strategy for its own orphan drug product.

Damages claim under a patent cross-undertaking

Representing a European manufacturer and supplier of generic pharmaceutical products and their UK distributor in litigation to obtain damages for exclusion from the UK market following the grant of an interim injunction in a patent case.

Advising on inventors rights

Advising medical inventors working for the NHS on their position regarding NHS intellectual property policy.